Clinical trials: Epirubicin
Esophageal Cancer, Extrahepatic Bile Duct Cancer
Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gastric Cancer, Head and Neck Cancer
- Trial name
- NCT00021047
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- 3 sites in United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Melanoma (Skin)
Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Sulindac may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by…
- Trial name
- NCT00755976
- Testing
- epirubicin hydrochloride, sulindac, immunologic technique
- Where
- 10 sites in Ireland
- Volunteers
- 32 people
- Sponsor
- Cancer Trials Ireland
Breast Cancer
Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study
Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe off-target side effects such as skeletal muscle deconditioning.
- Trial name
- PROTECT-06 (NCT05128617)
- Testing
- Epirubicin-cyclophosphamide, Paclitaxel
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Current guidelines as those from the AGO-Breast commission recommend for neoadjuvant breast cancer patients either a sequence of 4 cycles EC followed by 4 cycles of a taxane or 6 cycles of TAC based on previous large scale…
- Conditions
- Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer
- Trial name
- GeparSepto (NCT01583426)
- Testing
- nab-Paclitaxel, Paclitaxel
- Where
- Germany
- Volunteers
- 1,229 people
- Sponsor
- GBG Forschungs GmbH
Urinary Bladder Neoplasms, BCG Vaccine
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Previous studies have reported the efficacy of Bacillus Calmette-Guérin (BCG) combined with other drugs for the treatment of bladder cancer.
- Conditions
- Urinary Bladder Neoplasms, BCG Vaccine, Immunotherapy, Active, Multicenter Study
- Trial name
- NCT06441110
- Testing
- Tislelizumab in Combination with Bacillus Calmette-Guérin
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Fujian Medical University Union Hospital
Unspecified Adult Solid Tumor, Protocol Specific
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either…
- Trial name
- NCT00878904
- Testing
- epirubicin hydrochloride, panobinostat, gene expression analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- Beverly1 (NCT00820547)
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- 28 sites in France
- Volunteers
- 100 people
- Sponsor
- UNICANCER
Pancreatic Cancer
Gemcitabine or Combination Chemotherapy Followed by Chemoradiation for Stage IB, II, or III Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, epirubicin hydrochloride, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells…
- Trial name
- PACT-7 (NCT00960284)
- Testing
- capecitabine, cisplatin, epirubicin hydrochloride
- Where
- Italy
- Volunteers
- 102 people
- Sponsor
- IRCCS San Raffaele
Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Two regimen are currently considered to have highest efficacy for patients with high-risk early stage breast cancer: sequential treatment of high dose epirubicin, taxane, and cyclophosphamide concomitantly with a dual…
- Conditions
- Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS
- Trial name
- NCT02125344
- Testing
- non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel
- Where
- Germany
- Volunteers
- 961 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer
Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes
The purpose of this study is to determine whether a treatment with 4 cycles anthracycline + cyclophoshamide followed by administration of 4 cycles paclitaxel is more effective than therapy with 4 cy<cles of anthracycline…
- Trial name
- NCT00668616
- Testing
- Cyclophosphamide, Epirubicin, Paclitaxel, Epirubicin, Paclitaxel, Filgrastim
- Where
- Germany
- Volunteers
- 1,034 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Esophageal Cancer
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00381706
- Testing
- cetuximab, ECF, IC
- Where
- 227 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
This phase II trial compares the effect of adding darolutamide to standard therapy versus standard therapy alone before surgery for the treatment of patients with stage II-IIIA androgen receptor positive triple-negative breast…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
- Trial name
- NCT07016399
- Testing
- Biospecimen Collection, Breast Biopsy Procedure, Carboplatin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Vandana Abramson
Lymphoma
Long-Term Follow-up of Tandem High-Dose Therapy With Peripheral Blood Stem Cell for Adults With High-Risk Age-Adjusted IPI Aggressive Non-Hodgkin's Lymphomas
Phase II multicenter pilot trial (073) evaluating tandem HDT with PBSC support in aa-IPI=3 untreated aggressive NHL.
- Trial name
- 073 (NCT00869284)
- Testing
- CEEP regimen, Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)
- Where
- France
- Volunteers
- 45 people
- Sponsor
- French Innovative Leukemia Organisation
Breast Cancer
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
This is a prospective, multi-center, real-world study designed to evaluate the efficacy and safety of albumin-bound paclitaxel versus paclitaxel or docetaxel in adjuvant treatment of breast cancer.
- Trial name
- NCT05287308
- Testing
- doxorubicin, epirubicin, pirarubicin
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Chinese Academy of Medical Sciences
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
B-cell non-Hodgkin's lymphoma (B-NHL) is the most common type of NHL. Although novel immunotherapies represented by anti-CD20 monoclonal antibodies and CAR-T cell therapies have significantly improved the prognosis of B-NHL…
- Conditions
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT05097443
- Testing
- Orelabrutinib+R-CHOP; Orelabrutinib+R-DA-EPOCH; Orelabrutinib+R-HD MTX;Orelabrutinib+R+other chemotherapies
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Shandong Provincial Hospital
TNBC - Triple-Negative Breast Cancer
Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)
This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of treatment of TNBC breast cancer with neoadjuvant chemotherapy…
- Trial name
- NCT07351487
- Testing
- Neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab
- Where
- 2 sites in China
- Volunteers
- 37 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Breast Cancer Female
Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer
This was an open-label, randomized controlled trial that aims to compare the efficacy and safety of the concurrent neoadjuvant chemotherapy with endocrine therapy and neoadjuvant chemotherapy alone in ER-positive, HER2-negative…
- Trial name
- NCT02980965
- Testing
- letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel, fluorouracil, epirubicin, cyclophosphamide, docetaxel
- Where
- China
- Volunteers
- 249 people
- Sponsor
- Fudan University
Breast Cancer Organoids
Breast Cancer Treatment Based on Organ-like Culture
Based on the breast cancer organ platform, this experiment establishes a drug sensitivity test method that is closer to the body tumor in breast cancer, provides a basis for the accurate treatment of breast cancer, and discusses…
- Trial name
- NCT03925233
- Testing
- Trastuzumab, Doxorubicin Hydrochloride, Epirubicin hydrochloride
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Xijing Hospital
Peripheral T Cell Lymphoma
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
To evaluate the efficacy and safety of bortezomib combined with CHEP regimen in peripheral T cell lymphoma
- Trial name
- NCT04061772
- Testing
- Bortezomib, Etoposide, Cyclophosphamide
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Zhejiang Cancer Hospital
Breast Cancer
Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer
RATIONALE: 1. . To compare the effects on breast cancer of three different combinations of drugs which are commonly used to treat this disease. 2. . It is not yet known which treatment regimen is most effective for breast cancer.
- Trial name
- NCT00014222
- Testing
- epoetin alfa, filgrastim, cyclophosphamide
- Where
- 78 sites in United States, Canada
- Volunteers
- 2,104 people
- Sponsor
- NCIC Clinical Trials Group